Quoin Pharmaceuticals (QNRX) announced the release of the fourth episode in its NETHERTON NOW video series. This installment features Mandy Aldwin-Easton, a Netherton Syndrome patient.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals Reports Q2 2025 Financial Results
- Quoin Pharmaceuticals reports Q2 EPS ($6.28) vs ($13.68) last year
- Buy Rating for Quoin Pharmaceuticals: Promising Developments in Netherton Syndrome Treatment and Strategic Regulatory Advantages
- Quoin Pharmaceuticals provides update on its development product portfolio
- Quoin Pharmaceuticals CFO Departure Announcement